Djamgoz, Mustafa B. A. http://orcid.org/0000-0003-1435-8540
Article History
Received: 15 November 2023
Revised: 12 February 2024
Accepted: 14 February 2024
First Online: 29 February 2024
Competing interests
: MBAD holds shares in Celex Oncology Innovations Ltd. which is developing ion channel modulators, including ranolazine and its combinations, as anti-cancer drugs.